相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target
Nadia Alice Vieira Motta et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
Dawn O. Kleindorfer et al.
STROKE (2021)
Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997
Babak Sahragardjoonegani et al.
JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE (2021)
CSPS.com Trial of Adding Cilostazol to Antiplatelet Therapy to Reduce Recurrent Stroke
Graeme J. Hankey
STROKE (2020)
Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer's Disease
Masashi Tanaka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Cilostazol for Secondary Prevention of Stroke and Cognitive Decline Systematic Review and Meta-Analysis
Caroline McHutchison et al.
STROKE (2020)
Protocol: The Lacunar Intervention Trial 2 (LACI-2). A trial of two repurposed licenced drugs to prevent progression of cerebral small vessel disease
Joanna Wardlaw et al.
EUROPEAN STROKE JOURNAL (2020)
Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study
Jun-Young Lee et al.
NEUROTHERAPEUTICS (2019)
Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial
Kazunori Toyoda et al.
LANCET NEUROLOGY (2019)
Effects of Isosorbide Mononitrate and/or Cilostazol on Hematological Markers, Platelet Function, and Hemodynamics in Patients With Lacunar Ischaemic Stroke: Safety Data From the Lacunar Intervention-1 (LACI-1) Trial
Jason P. Appleton et al.
FRONTIERS IN NEUROLOGY (2019)
Small but Steady Steps in Stroke Medicine in Japan
Kazunori Toyoda et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients Within 48 Hours of Symptom Onset
Junya Aoki et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial
Gordon W. Blair et al.
ECLINICALMEDICINE (2019)
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
S. Claiborne Johnston et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites
Hye-In Lee et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Marie D. Gerhard-Herman et al.
CIRCULATION (2017)
Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study
Shu-Yu Tai et al.
NEUROTHERAPEUTICS (2017)
Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany
Jordi Castellsague et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2017)
Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique
Seong-Joon Lee et al.
BMC NEUROLOGY (2017)
Effect of cilostazol in treating diabetes-associated microvascular complications
Nicole J. Asal et al.
ENDOCRINE (2017)
Cilostazol exerts antiplatelet and anti-inflammatory effects through AMPK activation and NF-kB inhibition on hypercholesterolemic rats
Nadia Alice Vieira da Motta et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2016)
Confounding by Indication in Clinical Research
Demetrios N. Kyriacou et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Cilostazol but not sildenafil prevents memory impairment after chronic cerebral hypoperfusion in middle-aged rats
Jacqueline Godinho et al.
BEHAVIOURAL BRAIN RESEARCH (2015)
Cilostazol research in Asia: can it be applied to European and American patients?
Jong S. Kim et al.
INTERNATIONAL JOURNAL OF STROKE (2015)
Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions
Philip M. Bath et al.
INTERNATIONAL JOURNAL OF STROKE (2015)
A Randomized Comparison Study Assessing the Impact of Cilostazol on the Heart Rate and Arrhythmias by 24-Hour Ambulatory Holter Electrocardiographic Monitoring after Drug-Eluting Stent Implantation for Coronary Artery Disease-Results from the CILOHA (The randomized prospective impact of CILOstazol associated with Heart rate and Arrhythmias after percutaneous coronary intervention) Trial
Beom-June Kwon et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2015)
Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population
Aaron S. Kesselheim et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2015)
Validity of Diagnostic Codes for Acute Stroke in Administrative Databases: A Systematic Review
Natalie McCormick et al.
PLOS ONE (2015)
Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid
Takakuni Maki et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2014)
Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial
Wen-Hao Tang et al.
ENDOCRINE (2014)
Cilostazol for intermittent claudication
Rachel Bedenis et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Cilostazol: The Poor Man's Replacement of Drug-Eluting Stents and Balloons?
Thomas Zeller et al.
CIRCULATION (2013)
Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: A pilot study
Hirofumi Sakurai et al.
GERIATRICS & GERONTOLOGY INTERNATIONAL (2013)
Comparison of On-Treatment Platelet Reactivity Between Triple Antiplatelet Therapy With Cilostazol and Standard Dual Antiplatelet Therapy in Patients Undergoing Coronary Interventions: A Meta-Analysis
Hemang B. Panchal et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2013)
Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack
Yongjun Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles
Patrick Lacolley et al.
CARDIOVASCULAR RESEARCH (2012)
P2Y12 platelet inhibition in clinical practice
Peter Damman et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2012)
Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke
Oscar R. Benavente et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Anti-platelet therapy: phosphodiesterase inhibitors
Paolo Gresele et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Pharmacokinetic Comparison of Sustained- and Immediate-Release Oral Formulations of Cilostazol in Healthy Korean Subjects: A Randomized, Open-Label, 3-Part, Sequential, 2-Period, Crossover, Single-Dose, Food-Effect, and Multiple-Dose Study
Donghwan Lee et al.
CLINICAL THERAPEUTICS (2011)
Effect of Cilostazol Administration on Cerebral Hemodynamics and Rehabilitation Outcomes in Poststroke Patients
Shuji Matsumoto et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2011)
Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1
Hee-Doo Yoo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial
Yukito Shinohara et al.
LANCET NEUROLOGY (2010)
Incentives for Drug Development - The Curious Case of Colchicine
Aaron S. Kesselheim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Pharmacologic Therapy for Intermittent Claudication
Paul P. Dobesh et al.
PHARMACOTHERAPY (2009)
Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects)
William R. Hiatt et al.
JOURNAL OF VASCULAR SURGERY (2008)
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
Ralph L. Sacco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol
Masahiro Hiratsuka et al.
DRUG METABOLISM AND DISPOSITION (2007)
Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism
Ayako Hashimoto et al.
ATHEROSCLEROSIS (2006)
A concise history of gout and hyperuricemia and their treatment
George Nuki et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding
Shinya Goto
ATHEROSCLEROSIS SUPPLEMENTS (2005)
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial
HC Diener et al.
LANCET (2004)
Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro
ME Trujillo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Cilostazol as a unique antithrombotic agent
J Kambayashi et al.
CURRENT PHARMACEUTICAL DESIGN (2003)
Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication
PD Thompson et al.
AMERICAN JOURNAL OF CARDIOLOGY (2002)
New mechanism of action for cilostazol: Interplay between adenosine and cilostazol in inhibiting platelet activation
B Sun et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2002)
Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart
Y Shakur et al.
CARDIOVASCULAR DRUGS AND THERAPY (2002)
Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6
TM Lee et al.
ATHEROSCLEROSIS (2001)
Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta
T Nakamura et al.
LIFE SCIENCES (2001)
Research and development of cilostazol: An antiplatelet agent
T Nishi et al.
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN (2000)
Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication
YG Liu et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2000)
Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21
S Hayashi et al.
HYPERTENSION (2000)
分享论文
